Oracle's AI Order Book Swells as Free Cash Flow Sinks Into the Red
Published on 09/23/2026 at 19:50 | Editorial boerse-global.de
Oracle's push into artificial intelligence is producing a striking split-screen: a backlog that keeps climbing, and a cash position that keeps draining. The company's first-quarter results for fiscal 2027 captured both sides of that equation, with management booking more than $30 billion in fresh AI cloud contracts while remaining performance obligations ballooned to $664 billion. Adjusted earnings per share guidance for the full year was nudged up from $8.05 to $8.10.
Building the capacity to honor those commitments is another matter. Capital expenditures hit $28.5 billion in a single quarter, dragging free cash flow to a negative $5.40 billion. That gap between signed contracts and delivered infrastructure is the central tension facing the stock, and investors have taken notice. At around €129.00, the shares sit more than 54% below their 52-week high of €278.35 — a decline of more than half from the peak.
The strain has spilled over into credit markets. On September 18, the friction became visible as lenders pushed back on the financing terms underpinning Oracle's massive infrastructure program. Rising funding costs and on-the-ground delays can quickly unsettle the economics of these projects, a reminder that high-performance data centers run into physical and financial limits, not just engineering ones.
Cost-Cutting Runs Alongside the Buildout
Management is not standing still on expenses. Restructuring charges for fiscal 2026 are now expected to reach roughly $2.8 billion, up about $700 million from prior estimates. The program covers severance, contract terminations and layoffs as the company reshapes its cost base around a new operating reality. The most recent round of cuts removed 546 positions in the cloud infrastructure unit, and the stock has gained 4.7% since that move was disclosed a little over a week ago.
Should investors sell immediately? Or is it worth buying Oracle?
Clinical AI Moves to the Nursing Floor
While the balance sheet absorbs the buildout, Oracle is widening the reach of its industry-specific software. Its Clinical AI Agent, available to physicians since early 2024, is now being extended to nursing staff. The voice-driven tool navigates patient records, generates automated summaries and writes spoken notes directly into Oracle's electronic health record.
A human check remains mandatory: nurses must review and approve every entry before it is saved, a safeguard aimed at preventing treatment errors. Lifepoint Health, a hospital operator, began testing the speech-capture functions in live operations in early September.
Pharmaceutical work is expanding too. Oracle and IT services provider Wipro agreed yesterday to jointly offer pharmacovigilance services built on the Life Sciences Argus BPS platform, with Wipro handling operational onboarding and regulatory reporting for global clients. In the broader applications business, Manchester's 23,500-seat Co-op Live Arena will deploy Oracle's Simphony point-of-sale system alongside NetSuite, linking concession-stand transactions directly to central finance management.
A Demand Story With a Financing Problem
The new vertical solutions sit on top of a demand pipeline that shows no sign of cooling. Yet the stock's recovery remains fragile, and the shares continue to trade well below their 52-week peak. Wall Street is not uniformly bearish, and the bull case rests on the same backlog that worries the skeptics.
What matters now is conversion. Until Oracle can demonstrate that its enormous outlays reliably translate into free cash, the risk-reward profile stays demanding — and near-term caution is the more defensible stance.
Ad
Oracle Stock: New Analysis - 23 September
Fresh Oracle information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
